ACTRN12612000830897.

Study name	Mitochondrial agents in the treatment of bipolar disorder
Methods	Three‐arm, parallel randomised controlled trial
Participants	DSM‐IV bipolar disorder, current depressive phase (MADRS < 19), stable other therapy, 18+
Interventions	1. N‐acetylcysteine (NAC) capsules for 16 weeks (500 mg twice a day) 2. Acetyl L carnitine 500 mg + mitochondrial combination capsule + cardonutrient capsule for 16 weeks 3. Placebo treatment for 16 weeks
Outcomes	BL and every 4 weeks afterwards (6 visits) MADRS BDRS HAM‐A YMRS Impairment Functioning Tool SOFAS QLES‐Q CGI BP and CGI‐I Patient global impressions scale Change in blood oxidative and inflammatory markers
Starting date	4/3/2013
Contact information	Professor Michael Berk Mental Health Swanston Centre PO BOX 281 GEELONG VIC 3220 mikebe@barwonhealth.org.au
Notes	Recruiting